Cuprina Holdings (Cayman) Limited reported financial results for the first six months of 2025, showing a decrease in revenue and an increase in net loss compared to the previous year. The company’s CEO highlighted advancements in product diversification and geographic expansion during this period.

Key achievements included the completion of an IVF media production facility in Singapore and the setup of a laboratory in Saudi Arabia for manufacturing chronic wound treatment products. Cuprina also secured FDA approval to market medical maggots in the U.S. and obtained licensing rights for medical waste recycling technology in Southeast Asia.

Financially, Cuprina reported revenue of $18,040 for the six-month period, a gross profit of $302, and a net loss of $1,528,121. The company’s cash and cash equivalents stood at $3,216,540 as of June 30, 2025, with total assets of $8,482,098.

Looking ahead to 2026, Cuprina plans to focus on expanding its core MEDIFLY MDT business, launching iodine-based antiseptic products, and commercializing its medical waste recycling technology. The company aims to strengthen its leadership team and capabilities to support these initiatives and expects total revenue in 2026 to range from $1.0 to $1.5 million.

Investors can access Cuprina’s financial results for the first six months of 2025 through the company’s SEC filing or its investor relations website. Cuprina remains committed to delivering value for patients, partners, and shareholders in the upcoming year.

Read more at GlobeNewswire: Cuprina Holdings (Cayman) Limited Announces Financial